ATLANTA — Henry Nasrallah, MD, of the department of neurology and psychiatry at St. Louis University, discusses the utility of the recently FDA-approved Nuplazid for psychosis in Parkinson’s disease.
“Parkinson’s disease has many non-motor psychiatric symptoms, including psychosis. Up to 50% of Parkinson’s patients develop psychotic symptoms, which are predominantly visual hallucinations as well as delusions,” Nasrallah told Healio.com/Psychiatry. “These are obviously very disruptive symptoms and they get worse as disease progresses.”
Until now, there has been no medication intended for psychosis in Parkinson’s disease, according to Nasrallah.